Robin L Smith
CIK 1365035 · Executive Chair of the Board · last filed 2025-05-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$21.0K
Companies
11
Total Filings
95
Lifetime Open-Market Net
$54.69M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MTNB | Director | — | $0.78 | — | $0 | 1 | 2025-05-02 |
| CELUW | Director | 236,066 | $0.01 | $1.3K | $0 | 5 | 2023-06-16 |
| SRNE | Director | 135,000 | $0.00 | $68 | $90.9K | 5 | 2021-09-03 |
| CONCENTRIX SERVICESOURCE INC. (SREV) Delisted | Director | 167,975 | $1.50 | $252.0K | $85.0K | 3 | 2020-05-21 |
| SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Director | — | $0.39 | — | $0 | 2 | 2020-01-07 |
| RMTI | Director | 31,366 | $0.62 | $19.6K | $0 | 4 | 2019-06-10 |
| Emmaus Life Sciences, Inc. (MYNDW) Delisted | Director | 211,539 | — | — | $0 | 9 | 2019-05-10 |
| Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Director | 1,900 | — | — | $0 | 5 | 2017-02-07 |
| LISATA THERAPEUTICS, INC. (NBS) Delisted | Executive Chair of the Board | 347,285 | — | — | $24.8K | 11 | 2015-06-04 |
| LISATA THERAPEUTICS, INC. (NBS.WS) Delisted | Chairman of the Board and CEO | 1,659,533 | — | — | $37.7K | 32 | 2012-07-06 |
| LISATA THERAPEUTICS, INC. (NBS.U) Delisted | CEO and Chairman of the Board | 130,562 | — | — | $54.45M | 2 | 2007-10-01 |
Recent Filings · Page 4 of 10
95 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-14 | — | Grant (A) | +30,000 | $0 | |
| 2017-03-23 | RMTI | Grant (A) | +9,800 | $0 | EDGAR |
| 2017-02-07 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Exer (M) | +1,200 | $9.2K | EDGAR |
| 2016-12-14 | — | Buy (P) | +5,000 | $30.0K | |
| 2016-12-02 | — | Grant (A) | +16,000 | $100.0K | |
| 2016-11-02 | — | Grant (A) | +40,000 | $0 | |
| 2016-09-23 | — | Mixed | +20,776 | $103.9K | |
| 2016-09-23 | RMTI | Grant (A) | — | $0 | EDGAR |
| 2016-06-20 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-04-25 | — | Grant (A) | — | $0 |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.